Literature DB >> 32076837

Recent advancements in fabrication of nanomaterial based biosensors for diagnosis of ovarian cancer: a comprehensive review.

Rinky Sha1, Sushmee Badhulika2.   

Abstract

Ovarian cancer is commonly diagnosed via determination of biomarkers like CA125, Mucin 1, HE4, and prostasin that can be present in the blood. However, there is a substantial need for less expensive, simpler, and portable diagnostic tools, both for timely diagnosis and management of ovarian cancer. This review (with 101 refs.) discusses various kinds of nanomaterial-based biosensors for tumor markers. Following an introduction into the field, a first section covers different kinds of biomarkers for ovarian cancer including CA125 (MUC16), mucin 1 (MUC1), human epididymis protein 4 (HE4), and prostasin. This is followed by a short overview on conventional diagnostic approaches. A large section is then presented on biosensors for determination of ovarian cancer, with subsections on optical biosensors (fluorimetric, colorimetric, surface plasmon resonance, chemiluminescence, electrochemiluminescence), on electrochemical sensors, molecularly imprinted sensors, paper-based biosensors, microfluidic (lab-on-a-chip) assays, chemiresistive and field effect transistor-based sensors, and giant magnetoresistive sensors. Tables are presented that give an overview on the wealth of methods and materials. A concluding section summarizes the current status, addresses current challenges, and gives an outlook on potential future trends. Graphical abstract Schematic representation of the review covering the advancements in the fabrication of various nanomaterial based biosensors for diagnosis of ovarian cancer.

Entities:  

Keywords:  Biomarkers; CA125; Flexible FET, electrochemical; HE4; MUC1; Microfluidic; Molecular imprinting; Nanosensors; Prostasin

Year:  2020        PMID: 32076837     DOI: 10.1007/s00604-020-4152-8

Source DB:  PubMed          Journal:  Mikrochim Acta        ISSN: 0026-3672            Impact factor:   5.833


  71 in total

1.  Identification of serum biomarkers for ovarian cancer using MALDI-TOF-MS combined with magnetic beads.

Authors:  Shengjun Wu; Kai Xu; Guang Chen; Jun Zhang; Zhiwei Liu; Xinyou Xie
Journal:  Int J Clin Oncol       Date:  2011-06-03       Impact factor: 3.402

2.  Ultrasensitive electrochemical immunosensor for HE4 based on rolling circle amplification.

Authors:  Lingsong Lu; Bei Liu; Zhaohui Zhao; Cuixia Ma; Peng Luo; Chenggui Liu; Guoming Xie
Journal:  Biosens Bioelectron       Date:  2012-01-16       Impact factor: 10.618

3.  The use of bevacizumab to palliate symptomatic ascites in patients with refractory ovarian carcinoma.

Authors:  T Michael Numnum; Rodney P Rocconi; Jenny Whitworth; Mack N Barnes
Journal:  Gynecol Oncol       Date:  2006-06-23       Impact factor: 5.482

Review 4.  Electrochemical immunosensors in breast and ovarian cancer.

Authors:  Iulia Diaconu; Cecilia Cristea; Veronica Hârceagă; Giovanna Marrazza; Ioana Berindan-Neagoe; Robert Săndulescu
Journal:  Clin Chim Acta       Date:  2013-08-06       Impact factor: 3.786

5.  Construction of Tb-MOF-on-Fe-MOF conjugate as a novel platform for ultrasensitive detection of carbohydrate antigen 125 and living cancer cells.

Authors:  Minghua Wang; Mengyao Hu; Zhenzhen Li; Linghao He; Yingpan Song; Qiaojuan Jia; Zhihong Zhang; Miao Du
Journal:  Biosens Bioelectron       Date:  2019-07-25       Impact factor: 10.618

6.  Integration of cell phone imaging with microchip ELISA to detect ovarian cancer HE4 biomarker in urine at the point-of-care.

Authors:  Shuqi Wang; Xiaohu Zhao; Imran Khimji; Ragip Akbas; Weiliang Qiu; Dale Edwards; Daniel W Cramer; Bin Ye; Utkan Demirci
Journal:  Lab Chip       Date:  2011-09-01       Impact factor: 6.799

7.  A disposable paper-based electrochemical sensor with an addressable electrode array for cancer screening.

Authors:  Shenguang Ge; Lei Ge; Mei Yan; Xianrang Song; Jinghua Yu; Jiadong Huang
Journal:  Chem Commun (Camb)       Date:  2012-08-13       Impact factor: 6.222

8.  Ultrasensitive electrochemiluminescence immunoassay for simultaneous determination of CA125 and CA15-3 tumor markers based on PAMAM-sulfanilic acid-Ru(bpy)32+ and PAMAM-CdTe@CdS nanocomposite.

Authors:  Bahareh Babamiri; Rahman Hallaj; Abdollah Salimi
Journal:  Biosens Bioelectron       Date:  2017-07-28       Impact factor: 10.618

9.  The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms.

Authors:  Lynne Bingle; Vanessa Singleton; Colin D Bingle
Journal:  Oncogene       Date:  2002-04-18       Impact factor: 9.867

10.  The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.

Authors:  Ingegerd Hellström; John Raycraft; Martha Hayden-Ledbetter; Jeffrey A Ledbetter; Michèl Schummer; Martin McIntosh; Charles Drescher; Nicole Urban; Karl Erik Hellström
Journal:  Cancer Res       Date:  2003-07-01       Impact factor: 12.701

View more
  4 in total

1.  Early diagonosis of ovarian cancer: serum HE4, CA125 and ROMA model.

Authors:  Haixia Wang; Pingping Liu; Hai Xu; Hongmei Dai
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

Review 2.  Nanotechnological approaches for diagnosis and treatment of ovarian cancer: a review of recent trends.

Authors:  Haigang Ding; Juan Zhang; Feng Zhang; Yan Xu; Wenqing Liang; Yijun Yu
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

3.  Comprehensive analysis of genomic and immunological profiles in Chinese and Western hepatocellular carcinoma populations.

Authors:  Wei Li; Hong Wu; Xuewen Xu; Yange Zhang
Journal:  Aging (Albany NY)       Date:  2021-04-18       Impact factor: 5.682

Review 4.  Research Progress and Future Trends of Microfluidic Paper-Based Analytical Devices in In-Vitro Diagnosis.

Authors:  Taiyi Zhang; Feng Ding; Yujing Yang; Gaozhen Zhao; Chuanhao Zhang; Ruiming Wang; Xiaowen Huang
Journal:  Biosensors (Basel)       Date:  2022-07-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.